Trials / Completed
CompletedNCT00410371
Study to Compare Two Formulations of Lamotrigine in Healthy Subjects
An Open-label, Randomised, Single-dose, Parallel-group Study to Evaluate the Pharmacokinetic Characteristics, Safety and Tolerability of up to Two Formulations (With Different Taste Masking Approaches) of an Orally Disintegrating Tablet (ODT) of Lamotrigine at 25mg and 200mg Versus the Immediate Release (IR) Lamotrigine in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 96 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 19 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This study intends to compare the pharmacokinetic characteristics, safety and tolerability of two formulations of lamotrigine in healthy male and female volunteers
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lamotrigine | Lamotrigine |
| DRUG | GI267119 | 25 mg ODT |
Timeline
- Start date
- 2006-12-28
- Primary completion
- 2007-01-25
- Completion
- 2007-01-25
- First posted
- 2006-12-12
- Last updated
- 2017-09-12
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00410371. Inclusion in this directory is not an endorsement.